This is a phase I/II protocol investigating whether Nelfinavir can improve anemia and lower serum fibrosis biomarkers in Myelofibrosis patients.
≥18 years of age
Have a diagnosis of myelofibrosis (MF) according to the 2016 WHO criteria
Has a hemoglobin ≤ 10gm/dL at screening
Serum ferritin ≥ 100
Eastern Cooperative Oncology Group (ECOG) questionnaire score of ≥3
Currently pregnant or planning on being pregnant within the study period.
Currently taking Momelotinib or Pacritinib (these agents are purported to reduce hepcidin).
Currently taking any of the contraindicated medications to Nelfinavir listed in section 13.2